Article

HDAC inhibitors target IRS4 to enhance anti-androgen receptor (AR) therapy in AR-positive triple negative breast cancer

2023-01-30

Abstract excerpt

Triple negative breast cancer (TNBC) is the most malignant subtype of breast cancer. Androgen receptor (AR)-positive TNBC has been identified as a potential therapeutic target; however, clinical trials have not produced an effective treatment. This study aimed to identify a new treatment regimen to improve the prognosis of AR-positive TNBC. First, we used a combination of an AR inhibitor (enzalutamide, Enz) and se...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62a39bf6-e244-51a0-a729-26ec719c7129
DOI: 10.21203/rs.3.rs-2361617/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibitors target IRS4 to enhance anti-androgen receptor (AR) therapy in AR-positive triple negative breast cancerDOI 10.21203/rs.3.rs-2361617/v1Read

Multiple Molecular Subtypes of Triple-Negative Breast Cancer Critically Rely on Androgen Receptor and Respond to Enzalutamide <i>In Vivo</i>Semantic proximity Read

HDAC Inhibitors for the Therapy of Triple Negative Breast CancerSemantic proximity Read

Inavolisib-based Combination Therapy for the Treatment of PIK3CAMutated HR+/HER2- Breast Cancer: An Overview.Semantic proximity Read

Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer.Semantic proximity Read

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancerSemantic proximity Read

Integrated use of bioinformatic resources reveals that co-targeting of histone deacetylases, IKBK and SRC inhibits epithelial-mesenchymal transition in cancerSemantic proximity Read

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.Semantic proximity Read

Molecular Docking Appraisal of Dysphania ambrosioides Phytochemicals as Potential Inhibitor of a Key Triple-negative Breast Cancer Driver GeneSemantic proximity Read

Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsSemantic proximity Read

A Rational Drug Combination Design to Inhibit Epithelial-Mesenchymal Transition in a Three-Dimensional MicroenvironmentSemantic proximity Read

Reversal of endocrine resistance via N6AMT1-NEDD4L pathway-mediated p110α degradationSemantic proximity Read

Targeting Histone Deacetylases 6 in Dual-Target Therapy of CancerSemantic proximity Read